Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pucotenlimab - Lepu Biopharma

Next Previous
Drug Profile

Pucotenlimab - Lepu Biopharma

Alternative Names: Anti-PD-1-antibody - Lepu Biopharma; HX-008; Puyouheng; Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection - Lepu Biopharma

Latest Information Update: 24 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma; HanX Biopharmaceuticals
  • Developer Lepu Biopharma; Sun Yat-Sen University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma; Solid tumours
  • Phase III Gastrointestinal cancer
  • Phase II/III Non-small cell lung cancer
  • Phase II Bladder cancer; Breast cancer; Liver cancer; Nasopharyngeal cancer; Triple negative breast cancer
  • Phase 0 Gastric cancer

Most Recent Events

  • 30 May 2025 Updated efficacy and adverse events data from a phase II trial in Solid tumours and Gastrointestinal cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 15 May 2025 Phase-II clinical trials in Nasopharyngeal cancer (Combination therapy, In infants, In children, In adolescents, First-line therapy) in China (Parenteral) (NCT06969534)
  • 01 May 2025 Phase-0 for Gastric cancer (Late-stage disease, Combination therapy, Inoperable/Unresectable, Metastatic disease, First-line therapy) in China (IV) (NCT07356466)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top